Rifabutin-Based Triple Therapy (RHB-105) for Helicobacter pylori Eradication: A Double-Blind, Randomized, Controlled Trial.

Conclusion: These findings suggest potential for RHB-105 as first-line empirical H pylori therapy, addressing an unmet need in the current environment of increasing antibiotic resistance.
Primary Funding Source: RedHill Biopharma Ltd.
PMID: 32365359 [PubMed - as supplied by publisher]

Source: Annals of Internal Medicine - May 4, 2020 Category: Internal Medicine Authors: Graham DY, Canaan Y, Maher J, Wiener G, Hulten KG, Kalfus IN Tags: Ann Intern Med Source Type: research